Description
CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, Breyanzi, and Abecma have reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.
In total, financing rounds by CAR-T companies are approaching a total value of $4 billion, while CAR-T industry partnerships contribute another $2 billion.
M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead’s acquisition of Kite Pharma for $11.9 billion also made waves, as have other M&A transactions such as Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.
In aggregate, there has been nearly $100 billion of market capitalization from CAR-T companies within recent years. Ranging from small start-ups to billion dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.
CAR-T Market Overview
To track these industry events, BioInformant has released a 56-page CAR-T market brief.
It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships.
It also profiles 100+ market competitors that are involved with developing CAR-T technologies.
It features the following information for the CAR-T industry:
- Financing Rounds
- IPOs
- Asset Agreements
- Strategic Partnerships
- M&A Transactions
- Companies Profiles for 100+ CAR-T Competitors
Use it to:
- Quantify CAR-T industry investments
- Identify well-capitalized companies
- Scout potential partnerships and alliances
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
Summary
While this research was originally compiled for our own internal use, more and more clients have been requesting access to it. With the recent frenzy of CAR-T funding, it is time for you to take advantage of this rapidly expanding marketplace too.
Would you benefit from knowing all CAR-T industry investments and transactions worldwide?
If so, you’re down to your final hours to access this 56-page report for only $97 (50% off). When you claim it below, your PDF file will be available for immediate download with unlimited access and printing rights allowed.
Of course, your investment is backed by BioInformant’s 60-Day Money Back Guarantee.
